刘昆
团队名称：药物性肾损害防治创新团队
团队成员介绍：
博士，临床试验研究中心。
主要研究方向：临床药理学、药源性肾损伤的机制及防治研究
发表论文：
[1].Zhou LY, Liu K, Yin WJ, Xie YL, Wang JL, Zuo SR, Tang ZY, Wu YF, Zuo XC. Arginase2 mediates contrast-induced acute kidney injury via facilitating nitrosative stress in tubular cells. Redox Biol. 2023 Nov;67:102929.（IF=11.9，Q1，共同第一作者）
[2].Deng YX, Liu K, Qiu QX, Tang ZY, Que RM, Li DK, Gu XR, Zhou GL, Wu YF, Zhou LY, Yin WJ, Zuo XC. Identification and validation of hub genes in drug induced acute kidney injury basing on integrated transcriptomic analysis. Front Immunol. 2023 Mar 29;14:1126348.（IF=5.9，Q1，共同第一作者）
[3].Liu K, Hu C, Zhou LY, Tang ZY, Wu YF, Huang YJ, Zuo XC. The efficacy and safety of low-molecular-weight heparins for venous thromboembolism prophylaxis in abdominal or pelvic cancer surgery: A systematic review and network meta-analysis of randomized controlled trials. Thromb Res. 2025 Mar 2;249:109294.（IF=3.4，Q2，共同第一作者）
[4].Liu K, Hu C, Yin W, Zhou L, Gu X, Zuo X. An in vivo and in vitro model on the protective effect of cilnidipine on contrast-induced nephropathy via regulation of apoptosis and CaMKⅡ/mPTP pathway. J Biochem Mol Toxicol. 2023 Jan;37(1):e23238.（IF=2.8，Q2，共同第一作者）
[5].Liu K, Zhou LY, Li DY, Cheng WJ, Yin WJ, Hu C, Xie YL, Wang JL, Zuo SR, Chen LH, Zhou G, Zuo XC. A novel rat model of contrast-induced nephropathy based on dehydration. J Pharmacol Sci. 2019 Sep;141(1):49-55.（IF=2.9，Q2，第一作者）
[6].Gu X-R, Liu K, Deng Y-X, Xiang B-X, Zhou L-Y, Yin W-J, Huang J-X, Meng Y-C, Li D-K, Que R-M, Tang Z-Y, Zhou G-L, Wu Y-F, Huang Y-J, Zhou W-H, Zuo X-C. A renal-targeted gene delivery system derived from spermidine for arginase-2 silencing and synergistic attenuation of drug-induced acute kidney injury. Chemical Engineering Journal. 2024:150125.（IF=13.3，Q1，第二作者）
[7].Li DY, Yin WJ, Yi YH, Zhang BK, Zhao J, Zhu CN, Ma RR, Zhou LY, Xie YL, Wang JL, Zuo SR, Liu K, Hu C, Zhou G, Zuo XC. Development and validation of a more accurate estimating equation for glomerular filtration rate in a Chinese population. Kidney Int. 2019 Mar;95(3):636-646. （IF=14.8，Q1）